Does Your ACA Marketplace Plan Cover Wegovy or Zepbound?
If you buy insurance on healthcare.gov or your state's exchange, this is the coverage landscape you are actually working with - not the more generous employer-plan picture that dominates most GLP-1 coverage articles.
Why coverage is so rare
Anti-obesity medications are excluded from the Essential Health Benefits (EHB) categories ACA plans must cover, under Section 1927(d)(2) of the Social Security Act - a CMS clarification in January 2024 confirmed weight-management-only drugs are not a required EHB. A 2024 KFF review of federally facilitated Marketplace formularies found this plays out starkly: 82% of plans covered Ozempic (the same molecule, approved for diabetes) while only 1% covered Wegovy (approved for weight loss) - same drug family, radically different coverage, purely because of the FDA indication it is prescribed for.
Where coverage exists at all, it is because a specific state requires it through its own insurance mandate, not because of anything in federal ACA law.
The 9 states where coverage actually exists
California and North Dakota stand out - every carrier offering Marketplace plans in those two states covers GLP-1s for obesity. In the other 7 states, coverage exists but varies by carrier. Outside these 9 states, expect exclusion as the default, not the exception.
How 3 major Marketplace carriers handle it
Follows the federal EHB exclusion in most of its 25+ state markets. In mandate states, Ambetter has covered Zepbound on Gold or Platinum tier plans with prior authorization required. Check your specific state and plan tier.
Oscar's own published clinical guideline (Weight Loss Agents, PG070) lists Wegovy and Zepbound among covered agents where a plan includes them, requiring reauthorization every 6 months based on documented lifestyle modification and clinically meaningful weight loss. This describes how coverage works when present, not a guarantee every Oscar plan includes it.
Excludes Wegovy for weight loss in most states, consistent with the federal EHB exclusion. In California specifically, Molina Marketplace plans cover both Wegovy (up to 2.4 mg daily, 5 pens per 30 days) and Zepbound (up to 15 mg weekly, 4 pens per 28 days) with defined dose limits - one of the clearest examples of the mandate-state pattern in practice.
If your plan excludes it, what are your options?
- Check for a secondary-indication path.Wegovy covers cardiovascular risk reduction in patients with established cardiovascular disease and overweight/obesity; Zepbound covers moderate-to-severe obstructive sleep apnea. Some plans that exclude "weight loss alone" still cover the drug under these on-label secondary uses.
- Confirm your BMI meets the (usually stricter) marketplace threshold. Even in mandate states, most carriers require BMI 40+ rather than the more common 30+ threshold used elsewhere, plus 3-9 months of documented diet/exercise participation with proof it did not work.
- Compare cash-pay paths. If your plan excludes coverage entirely, manufacturer self-pay programs (NovoCare for Wegovy, LillyDirect for Zepbound) are often cheaper than paying full list price out of pocket - see the without-insurance guides linked below.
- Re-check during open enrollment. Coverage is genuinely volatile year-to-year on Marketplace plans - a plan that excluded coverage last year is not guaranteed to exclude it next year, and vice versa.
Frequently asked questions
Does my ACA Marketplace plan cover Wegovy or Zepbound for weight loss?
Probably not, but check your specific state and plan. Research reviewing all 300 carriers offering 2026 Marketplace plans found only 26 (8.7%) cover a GLP-1 for obesity at all, and those 26 are concentrated in just 9 states: California, North Dakota, New York, Vermont, Pennsylvania, West Virginia, Rhode Island, Delaware, and Georgia. In California and North Dakota specifically, every carrier offering plans covers it; everywhere else, coverage is the exception, not the rule.
Why do so few Marketplace plans cover these drugs?
Federal law is the root cause, not insurer stinginess. Anti-obesity medications are excluded from the Essential Health Benefits (EHB) that ACA plans are required to cover, under Section 1927(d)(2) of the Social Security Act - a CMS clarification in January 2024 confirmed weight-management-only drugs are not a required EHB. States that require coverage anyway ("mandate states") are doing so through their own state insurance law, not federal requirement. That is why coverage clusters so heavily in a handful of states rather than being nationally consistent.
Does Ambetter (Centene) cover Wegovy or Zepbound?
In most states, no - Ambetter follows the federal EHB exclusion across nearly all its 25+ state markets. Where a state mandate requires coverage, Ambetter has covered Zepbound on Gold or Platinum tier plans with prior authorization required - the same mandate-state pattern as the rest of the market. If you have Ambetter, check your specific state and plan tier rather than assuming either way.
Does Oscar Health cover Wegovy or Zepbound?
Oscar's own published clinical guideline (Weight Loss Agents, PG070) lists Wegovy and Zepbound among covered weight-loss agents where the plan covers them, requiring reauthorization every 6 months contingent on documented lifestyle modification and clinically meaningful weight loss. Whether your specific Oscar plan covers them at all still depends on your state and plan tier - the clinical guideline describes how coverage works when a plan includes it, not that every Oscar plan does.
Does Molina cover Wegovy or Zepbound?
It depends heavily on your state. Molina's marketplace plans exclude Wegovy for overweight/obesity in most states, consistent with the federal EHB exclusion. In California specifically, Molina's Marketplace plans do cover both Wegovy (up to 2.4 mg daily, 5 pens per 30 days) and Zepbound (up to 15 mg weekly, 4 pens per 28 days) with defined dose limits - California being one of the 9 mandate states where coverage is broadly available. Outside mandate states, expect exclusion.
If my plan excludes GLP-1s for weight loss, are there any exceptions?
Yes, two common ones. First, if you have an FDA-approved secondary indication - cardiovascular risk reduction for Wegovy in patients with established cardiovascular disease and overweight/obesity, or moderate-to-severe obstructive sleep apnea for Zepbound - some plans that exclude "weight loss alone" will still cover the drug under that secondary indication. Second, even in mandate states, coverage typically requires BMI 40+ (not the more common 30+ threshold) and documented participation in a diet/exercise program for 3-9 months with proof you were unable to lose weight that way first - the bar is real even where coverage technically exists.
Is coverage getting better or worse over time?
Worse, on current data. The same 2026 research found the number of Marketplace enrollees with access to obesity coverage for GLP-1s dropped from about 3.6 million in 2024 to about 2.8 million in 2026 - a real decline, not a static picture. This tracks the broader pattern documented elsewhere on this site of state Medicaid programs and employer plans also pulling back GLP-1 coverage through 2025-2026 as drug costs strain budgets.
Sources
- KFF, "Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans," June 12, 2024 (federally facilitated Marketplace formulary review).
- Leverage/AXIACI research (funded by the Robert Wood Johnson Foundation), review of all 300 carriers offering 2026 ACA Marketplace plans.
- Oscar Health Clinical Guideline PG070 (Weight Loss Agents), published policy document.
- Molina Healthcare Marketplace drug and biologic coverage criteria (California).
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.